Timothy Murray, MD
Retina Specialist · South Miami, FLNPI 1891710851
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $118,620 of the $132,611 with a category attached, or 89.4%. Alcon accounts for 92.9% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $36,822 and has fallen 99.9% since, to $45 in 2025. Among retina specialist clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 91 payments — averaging $1457.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$123K
- Novartis$6K
- Heidelberg Engineering, Inc.$3K
- Genentech USA, Inc.$419
- Aerie Pharmaceuticals, Inc.$177
- Bausch & Lomb, A Division Of Bausch Health US, LLC$165
- plus $210 from 3 others
Across 3 payments — averaging $17,095 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$48K
- Novartis Pharma AG$3K
What the payments were for
- Consulting fees$118,62089%
- Speaking & faculty fees$3,5503%
- Travel & lodging$6,4265%
- Food & beverage$4,0153%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 65 | $123,209 |
| Novartis | 4 | $5,932 |
| Heidelberg Engineering, Inc. | 2 | $2,500 |
| Genentech USA, Inc. | 5 | $419 |
| Aerie Pharmaceuticals, Inc. | 8 | $177 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $165 |
| Dutch Ophthalmic, USA | 1 | $107 |
| AbbVie | 3 | $78 |
| Apellis Pharmaceuticals, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Constellation$89,874
- NGENUITY$28,324
- Luxor$11,843
- Alcon Greishaber Finesse$11,698
- FINESSE SHARKSKIN$8,400
- BEOVU$5,913
- Spectralis$2,500
- Lucentis$146
- VISUDYNE$144
- SUSVIMO$127
- EVA, combined machine$107
- MARLO$107
How this compares
$132,611 in reported general payments places this provider in the 90th percentile of 118 retina specialist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 15 | $55,544 |
| RestasisCyclosporine | 28 | $21,238 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,371 | $19,994 |
| LumiganBimatoprost | 33 | $19,923 |
| Dorzolamide Hcl | 919 | $17,175 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 92 | $11,499 |
| RhopressaNetarsudil Mesylate | 34 | $10,919 |
| Prednisolone Acetate | 212 | $10,725 |
| Gentamicin Sulfate | 966 | $10,113 |
| XiidraLifitegrast | 12 | $8,245 |
| Bromfenac Sodium | 37 | $7,087 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $6,321 |
| Alphagan PBrimonidine Tartrate | 15 | $6,131 |
| Brimonidine Tartrate | 364 | $5,208 |
| RocklatanNetarsudil Mesylat/Latanoprost | 12 | $4,707 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $78 | $53,61394 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $177 | $15,62646 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 118 retina specialist providers in Florida.
Other retina specialist in South Miami
- Sunil GuptaPensacola$1.8M
- Joseph NezgodaWest Palm Beach$600K
- Eduardo UchiyamaFt Lauderdale$356K
- Thomas AlbiniMiami$281K
- Audina BerrocalMiami$210K
- Philip RosenfeldMiami$206K
- John MyersPensacola$152K
- Adiel SmithAventura$116K
- Paul GalloglyPalm Beach Gardens$72K
- John LehrOrlando$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.